Kewaunee Scientific Corporation's First Quarter Summary
Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced its financial results for the first quarter of fiscal year 2025. The company reported sales of $48,393,000, reflecting a slight decrease of 2.9% from the same quarter last year, when sales amounted to $49,839,000.
Financial Results and Key Metrics
In the first quarter, pre-tax earnings were reported at $2,430,000, down from $3,412,000 in the prior year's first quarter, representing a 28.8% decrease. The net earnings for this quarter were $2,193,000, which is lower than the net earnings of $2,474,000 recorded during the same period last year. EBITDA for the quarter was $3,325,000, down from $4,305,000 in the previous year.
Analysis of Order Backlog and Segments
As of July 31, 2024, the company’s order backlog reached $159.4 million, a notable increase from $140.8 million a year earlier. While domestic sales saw a slight increase to $35,523,000, the international segment faced challenges, with sales dropping to $12,870,000 due to delays affecting various projects.
Insights into the Domestic Segment
The domestic segment performed better, achieving net earnings of $2,871,000, an increase from $2,711,000 last year. This segment also reported an EBITDA of $4,738,000, up from $4,578,000 the previous year, indicating consistent demand and stable performance across its markets.
Challenges in the International Segment
On the other hand, the international segment experienced a significant sales decline, dropping by 10.7% compared to last year. Delays at customer construction sites, especially in countries like India, affected shipments and delivery times, highlighting the challenges in these regions.
Performance of the Corporate Segment
In the corporate segment, Kewaunee recorded a pre-tax net loss of $1,992,000, worse than the loss of $1,004,000 the previous year. This decline is mainly due to increased professional service fees not directly tied to core operations and changes in how costs are allocated across different business segments.
Future Outlook
Kewaunee Scientific's total cash on hand was $25,186,000, showing a decrease from the previous quarter. Despite a slight rise in working capital and short-term debt, long-term obligations saw a minor reduction. CEO Thomas D. Hull III highlighted the solid performance for the quarter, pointing out positives such as a strong order backlog and robust quoting activity for upcoming projects.
Contact Information
For more information, please contact Donald T. Gardner III at 704/871-3274.
Frequently Asked Questions
1. What were the total sales for Kewaunee Scientific in the first quarter?
The total sales for the quarter were $48,393,000.
2. How did the net earnings compare to the previous year?
Net earnings fell from $2,474,000 to $2,193,000 compared to the same quarter last year.
3. What challenges is the international segment facing?
The international segment is dealing with delays caused by issues at customer construction sites, particularly noted in India.
4. What is the current order backlog for Kewaunee Scientific?
The current order backlog stands at $159.4 million as of July 31, 2024.
5. Who can be contacted for investor relations?
For inquiries, investors can reach out to Donald T. Gardner III at 704/871-3274.
